RA0250

antibody from Oursmab

Targeting: FGF23

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0250

Provider

Oursmab

Product name

Burosumab (Biosimilar Reference Antibody) (FGF23)

Antibody type

Monoclonal

Description

Burosumab is a groundbreaking, fully human monoclonal antibody specifically approved for the treatment of X-linked hypophosphatemia, a rare, inherited form of rickets and osteomalacia caused by a genetic defect in the PHEX gene. Marketed under the brand name Crysvita?, it represents the first and only therapy that targets the underlying pathophysiology of the disease rather than just supplementing phosphate and vitamin D. Burosumab is administered via subcutaneous injection and has been shown in clinical trials to significantly improve phosphate levels, bone healing, growth in children, and reduce pain and stiffness in adults.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Burosumab (Biosimilar Reference Antibody) (FGF23)-RA0250-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Burosumab (Biosimilar Reference Antibody) (FGF23)-RA0250 in a linear range of 3.91-125 ng/mL.